ADAM10 as a Target for Anti-Cancer Therapy

Author(s): Marcia L. Moss, Alexander Stoeck, Wenbo Yan, Peter J. Dempsey.

Journal Name: Current Pharmaceutical Biotechnology

Volume 9 , Issue 1 , 2008

Become EABM
Become Reviewer

Abstract:

There is a great unmet medical need in the area of cancer treatment. A potential therapeutic target for intervention in cancer is ADAM10. ADAM10 is a disintegrin-metalloproteinase that processes membrane bound proteins from the cell surface to yield soluble forms. Pharmaceutical companies are actively seeking out inhibitors of ADAM10 for treatments in cancer as the enzyme is known to release the ErbB receptor, HER2/ErbB2 from the cell membrane, an event that is necessary for HER2 positive tumor cells to proliferate. ADAM10 is also capable of processing betacellulin indicating that an inhibitor could be used against EGFR/ErbB1 and/or HER4/ErbB4 receptor positive tumor cells that are betacellulin- dependent. ADAM10 is the principle sheddase for several other molecules associated with cancer proliferation, differentiation, adhesion and migration such as Notch, E-cadherin, CD44 and L1 adhesion molecule indicating that targeting ADAM10 with specific inhibitors could be beneficial.

Keywords: CD44 shedding, Cell adhesion molecules, tumorigenesis, Notch signaling pathway, Epidermal growth factor

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 1
Year: 2008
Page: [2 - 8]
Pages: 7
DOI: 10.2174/138920108783497613

Article Metrics

PDF: 56